TransMedics Group (NASDAQ:TMDX) Releases Earnings Results, Misses Expectations By $0.17 EPS

TransMedics Group (NASDAQ:TMDX) released its earnings results on Monday. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17), Briefing.com reports. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same quarter in the previous year, the company posted ($0.12) earnings per share. The business’s revenue was up 63.7% compared to the same quarter last year. TransMedics Group updated its FY 2024 guidance to EPS.

TransMedics Group Price Performance

TMDX traded down $6.58 on Wednesday, reaching $81.92. The stock had a trading volume of 4,524,838 shares, compared to its average volume of 931,404. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $177.37. The firm has a 50-day moving average of $146.02 and a 200-day moving average of $140.16. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of 90.30 and a beta of 1.99.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on TMDX shares. Robert W. Baird lowered their price target on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday. JPMorgan Chase & Co. lowered their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday. Piper Sandler reissued an “overweight” rating and set a $180.00 price target on shares of TransMedics Group in a report on Tuesday. Baird R W raised TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Finally, Oppenheimer lowered their price target on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a report on Tuesday. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Buy” and an average target price of $144.80.

Insiders Place Their Bets

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,180,642.53. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the sale, the insider now owns 20,843 shares in the company, valued at approximately $3,089,766.32. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at $8,180,642.53. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 64,205 shares of company stock valued at $9,981,907 in the last 90 days. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.